BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 25253787)

  • 1. Antibody against granulin-epithelin precursor sensitizes hepatocellular carcinoma to chemotherapeutic agents.
    Wong NC; Cheung PF; Yip CW; Chan KF; Ng IO; Fan ST; Cheung ST
    Mol Cancer Ther; 2014 Dec; 13(12):3001-12. PubMed ID: 25253787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Granulin-epithelin precursor is an oncofetal protein defining hepatic cancer stem cells.
    Cheung PF; Cheng CK; Wong NC; Ho JC; Yip CW; Lui VC; Cheung AN; Fan ST; Cheung ST
    PLoS One; 2011; 6(12):e28246. PubMed ID: 22194816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Granulin-epithelin precursor and ATP-dependent binding cassette (ABC)B5 regulate liver cancer cell chemoresistance.
    Cheung ST; Cheung PF; Cheng CK; Wong NC; Fan ST
    Gastroenterology; 2011 Jan; 140(1):344-55. PubMed ID: 20682318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic cancer stem cell marker granulin-epithelin precursor and β-catenin expression associate with recurrence in hepatocellular carcinoma.
    Cheung PF; Cheung TT; Yip CW; Ng LW; Fung SW; Lo CM; Fan ST; Cheung ST
    Oncotarget; 2016 Apr; 7(16):21644-57. PubMed ID: 26942873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granulin-epithelin precursor renders hepatocellular carcinoma cells resistant to natural killer cytotoxicity.
    Cheung PF; Yip CW; Wong NC; Fong DY; Ng LW; Wan AM; Wong CK; Cheung TT; Ng IO; Poon RT; Fan ST; Cheung ST
    Cancer Immunol Res; 2014 Dec; 2(12):1209-19. PubMed ID: 25315249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granulin-epithelin precursor interacts with 78-kDa glucose-regulated protein in hepatocellular carcinoma.
    Yip CW; Lam CY; Poon TCW; Cheung TT; Cheung PFY; Fung SW; Wang XQ; Leung ICY; Ng LWC; Lo CM; Tsao GSW; Cheung ST
    BMC Cancer; 2017 Jun; 17(1):409. PubMed ID: 28601093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Granulin-epithelin precursor as a therapeutic target for hepatocellular carcinoma.
    Ho JC; Ip YC; Cheung ST; Lee YT; Chan KF; Wong SY; Fan ST
    Hepatology; 2008 May; 47(5):1524-32. PubMed ID: 18393387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA interference against granulin-epithelin precursor prevents hepatocellular carcinoma growth: its application as a therapeutic agent.
    Park MY; Park YS; Nam JH
    Int J Oncol; 2011 Oct; 39(4):853-61. PubMed ID: 21701774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Granulin-epithelin precursor overexpression promotes growth and invasion of hepatocellular carcinoma.
    Cheung ST; Wong SY; Leung KL; Chen X; So S; Ng IO; Fan ST
    Clin Cancer Res; 2004 Nov; 10(22):7629-36. PubMed ID: 15569995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and characterization of tropomyosin 3 associated with granulin-epithelin precursor in human hepatocellular carcinoma.
    Lam CY; Yip CW; Poon TC; Cheng CK; Ng EW; Wong NC; Cheung PF; Lai PB; Ng IO; Fan ST; Cheung ST
    PLoS One; 2012; 7(7):e40324. PubMed ID: 22792281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
    Jiang H; Dong Q; Luo X; Shi B; Wang H; Gao H; Kong J; Zhang J; Li Z
    Cancer Lett; 2014 Jan; 342(1):113-20. PubMed ID: 24007863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Akt/hypoxia-inducible factor-1alpha/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells.
    Lau CK; Yang ZF; Ho DW; Ng MN; Yeoh GC; Poon RT; Fan ST
    Clin Cancer Res; 2009 May; 15(10):3462-71. PubMed ID: 19447872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of ZFX confers self-renewal and chemoresistance properties in hepatocellular carcinoma.
    Lai KP; Chen J; He M; Ching AK; Lau C; Lai PB; To KF; Wong N
    Int J Cancer; 2014 Oct; 135(8):1790-9. PubMed ID: 24585547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Smad3 Sensitizes Hepatocelluar Carcinoma Cells to Cisplatin by Repressing Phosphorylation of AKT.
    Zhou HH; Chen L; Liang HF; Li GZ; Zhang BX; Chen XP
    Int J Mol Sci; 2016 Apr; 17(4):. PubMed ID: 27110775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel biomarkers GEP/ABCB5 regulate response to adjuvant transarterial chemoembolization after curative hepatectomy for hepatocellular carcinoma.
    Chong CC; Cheung ST; Cheung YS; Chan AW; Chan SL; Yu SC; Lai PB
    Hepatobiliary Pancreat Dis Int; 2018 Dec; 17(6):524-530. PubMed ID: 30413348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tunicamycin potentiates cisplatin anticancer efficacy through the DPAGT1/Akt/ABCG2 pathway in mouse Xenograft models of human hepatocellular carcinoma.
    Hou H; Sun H; Lu P; Ge C; Zhang L; Li H; Zhao F; Tian H; Zhang L; Chen T; Yao M; Li J
    Mol Cancer Ther; 2013 Dec; 12(12):2874-84. PubMed ID: 24130050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BPTF promotes hepatocellular carcinoma growth by modulating hTERT signaling and cancer stem cell traits.
    Zhao X; Zheng F; Li Y; Hao J; Tang Z; Tian C; Yang Q; Zhu T; Diao C; Zhang C; Chen M; Hu S; Guo P; Zhang L; Liao Y; Yu W; Chen M; Zou L; Guo W; Deng W
    Redox Biol; 2019 Jan; 20():427-441. PubMed ID: 30419422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model.
    Teng KY; Han J; Zhang X; Hsu SH; He S; Wani NA; Barajas JM; Snyder LA; Frankel WL; Caligiuri MA; Jacob ST; Yu J; Ghoshal K
    Mol Cancer Ther; 2017 Feb; 16(2):312-322. PubMed ID: 27980102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DLK1 as a potential target against cancer stem/progenitor cells of hepatocellular carcinoma.
    Xu X; Liu RF; Zhang X; Huang LY; Chen F; Fei QL; Han ZG
    Mol Cancer Ther; 2012 Mar; 11(3):629-38. PubMed ID: 22238367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.